论文部分内容阅读
目的:评估纳洛酮治疗肝硬化工临床型肝性脑病(SHE)的疗效。方法:47例SHE随机分为治疗组24例(A组),对照组23例(B组)。双盲法分别给予治疗组纳洛酮0.4 mg(1mL)、对照组0.9%氯化钠1mL,均1日 1次肌肉注射,连用 10日。用药前后分别行数字连接试验(NCT)、数字符号试验(DS)检测及测定血氨,并随访有否发生临床型肝性脑病。结果:治疗组治疗后 NCT、 DS均比治疗前明显改善,P<0.01,且无1例发展为临床型肝性脑病。不良反应轻微。对照组治疗前后NCT、OS无变化,发生临床型肝性脑病3例。结论:纳洛酮是一种有效、安全的SHE治疗药物,值得临床推广试用。
Objective: To evaluate the efficacy of naloxone in the treatment of clinical hepatic encephalopathy (SHE) in cirrhosis. Methods: Forty-seven SHE were randomly divided into treatment group (24 cases) and control group (23 cases). Double-blind method were given to the treatment group naloxone 0.4 mg (1 mL), the control group 0.9% sodium chloride 1 mL, were intramuscularly on the 1st, once every 10 days. Before and after treatment, digital connection test (NCT), digital sign test (DS) were used to detect and measure blood ammonia, and whether clinical hepatic encephalopathy was followed up. Results: After treatment, the NCT and DS of the treatment group were significantly improved than those before treatment, P <0.01, and none of them developed clinical hepatic encephalopathy. Minor adverse reactions. The control group before and after treatment NCT, OS no change, the occurrence of clinical hepatic encephalopathy in 3 cases. Conclusion: Naloxone is an effective and safe drug for SHE and worthy of clinical trial.